Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL-C not adequately controlled with maximally tolerated statin therapy.
Critère d'inclusion
- Dyslipidemia